Why Twist Bioscience (TWST) Is Up 17.2% After Revenue Beat And Bullish Analyst Coverage

• Earlier this week, Twist Bioscience reported a 16.9% increase in revenue, accompanied by broadly favorable analyst coverage with eight buy ratings and no sell ratings, underscoring growing interest in its synthetic DNA-based products and collaborations.
• This combination of faster revenue growth and uniformly positive analyst sentiment highlights how Twist’s technology platform and partnerships are increasingly resonating with the market despite ongoing financial challenges.
• Now, we’ll examine how this stronger-than-expected revenue momentum influences Twist Bioscience’s existing investment narrative around growth, margins, and customer concentration.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you need to believe its synthetic DNA platform can scale into a much larger revenue base before funding constraints bite. The 16.9% revenue increase and unified buy ratings support the near term growth catalyst, but they do not remove the central risk that continuing losses and negative margins could eventually require additional capital.

Among recent announcements, Twist’s raised fiscal 2024 and 2025 revenue guidance stands out, because it ties directly to this stronger revenue print and reinforces the story of improving top line momentum as a key catalyst.

Yet investors should also be aware that persistent losses and the possibility of future dilution mean…

Read the full narrative on Twist Bioscience (it’s free!)

Twist Bioscience’s narrative projects $575.2 million revenue and $92.4 million earnings by 2028.

Uncover how Twist Bioscience’s forecasts yield a $35.62 fair value, a 14% downside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have three fair value estimates for Twist Bioscience, clustered between US$35.47 and US$42. These views sit alongside concerns that ongoing losses and potential dilution could weigh on the longer term outcome, so it makes sense to compare several perspectives before forming your own.

Explore 3 other fair value estimates on Twist Bioscience – why the stock might be worth as much as $42.00!

Build Your Own Twist Bioscience Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Twist Bioscience research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Twist Bioscience’s overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com